We are live on ! Find out more
GYRE icon

Gyre Therapeutics

63 hedge funds and large institutions have $66.4M invested in Gyre Therapeutics in 2019 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 22 increasing their positions, 24 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

65% more capital inflows, than outflows

Capital inflows: $16.2M | Capital outflows: $9.8M

19% more call options, than puts

Call options by funds: $598K | Put options by funds: $504K

5.5% more ownership

Funds ownership: 62.92% → 68.42% (+5.5%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

8% less repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 24

3% less funds holding

Funds holding: 65 → 63 (-2)

13% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 8

Holders
63
Holders Change
-2
Holders Change %
-3.08%
% of All Funds
1.36%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
7
Increased
22
Reduced
24
Closed
8
Calls
$598​K
Puts
$504​K
Net Calls
+$94​K
Net Calls Change
-⁠$59​K

GYRE Hedge Fund Activity: Q1 2019 in Review

63 of the 4,635 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q1 2019, worth a combined $66.4M — up 12% from $59.3M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of GYRE and 7 opened new positions — a net loss of 1 holder — while 24 trimmed existing stakes and 22 added.

The largest buyer was Vanguard Group, adding an estimated $2.71M. The largest seller was Marshall Wace, cutting an estimated $3M.

  • 63 institutional investors held Gyre Therapeutics (GYRE) as of Q1 2019, down from 65 in Q4 2018.
  • Funds reported $66.4M of Gyre Therapeutics stock for Q1 2019, up 12% quarter-over-quarter.
  • 7 funds opened new Gyre Therapeutics positions in Q1 2019 and 8 closed out, a net change of -1 holder.
  • The largest Gyre Therapeutics buyer in Q1 2019 was Vanguard Group, an estimated $2.71M added.
  • The largest Gyre Therapeutics seller in Q1 2019 was Marshall Wace, an estimated $3M sold.

Based on aggregated 13F filings for Q1 2019.